CHO-H01 / Cho Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   2 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CHO-H01 / Cho Pharma
NCT05950165: A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Recruiting
1/2
37
US, RoW
CHO-H01, CHO-H01 at RP2D, Lenalidomide
Cho Pharma Inc.
Non-Hodgkin Lymphoma
12/25
06/26

Download Options